Celcuity (NASDAQ:CELC) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of Celcuity (NASDAQ:CELC) from a sell rating to a hold rating in a research note published on Saturday morning.

Several other brokerages have also issued reports on CELC. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celcuity in a research note on Wednesday, January 21st. Needham & Company LLC reissued a “buy” rating and set a $122.00 price objective on shares of Celcuity in a report on Thursday. Jefferies Financial Group upped their target price on shares of Celcuity from $108.00 to $134.00 and gave the company a “buy” rating in a research report on Tuesday, December 2nd. Stifel Nicolaus raised their target price on shares of Celcuity from $115.00 to $125.00 and gave the company a “buy” rating in a research note on Thursday. Finally, Wolfe Research reiterated an “outperform” rating and set a $110.00 price target on shares of Celcuity in a research report on Thursday, March 12th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $109.88.

Celcuity Price Performance

Shares of CELC stock opened at $106.02 on Friday. Celcuity has a 1 year low of $7.57 and a 1 year high of $120.32. The firm’s 50 day moving average is $109.49 and its 200-day moving average is $90.95. The firm has a market capitalization of $4.91 billion, a price-to-earnings ratio of -27.97 and a beta of 0.38. The company has a current ratio of 12.26, a quick ratio of 12.26 and a debt-to-equity ratio of 2.74.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings data on Wednesday, March 25th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.06) by $0.09. Sell-side analysts forecast that Celcuity will post -2.62 EPS for the current fiscal year.

Insider Buying and Selling

In other Celcuity news, Director David Dalvey sold 20,000 shares of the stock in a transaction dated Tuesday, January 27th. The stock was sold at an average price of $120.03, for a total value of $2,400,600.00. Following the transaction, the director owned 90,000 shares of the company’s stock, valued at approximately $10,802,700. This represents a 18.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 15.77% of the company’s stock.

Hedge Funds Weigh In On Celcuity

Several institutional investors and hedge funds have recently made changes to their positions in the company. EverSource Wealth Advisors LLC increased its position in shares of Celcuity by 1,329.2% in the 4th quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock valued at $34,000 after buying an additional 319 shares in the last quarter. Meeder Asset Management Inc. bought a new position in Celcuity during the fourth quarter worth about $42,000. Ogorek Anthony Joseph NY ADV acquired a new position in Celcuity in the third quarter valued at about $27,000. US Bancorp DE grew its stake in Celcuity by 25.4% in the third quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after acquiring an additional 143 shares during the period. Finally, NBC Securities Inc. bought a new stake in shares of Celcuity in the fourth quarter worth about $99,000. Institutional investors and hedge funds own 63.33% of the company’s stock.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.